Loading organizations...
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Nov 7, 2025 | Onchilles Pharma | $25.0M Series A | — | Kennedy Lewis Investment Management, Lincoln Park Capital, LYZZ Capital, University of Chicago Medicine |
| Nov 1, 2023 | Alto Neuroscience | $45.0M Series C | Michael Liang | 7BC Venture Capital, Baird Capital, Champion Hill Labs, Crosscut Ventures, Endeavor Venture Funds, Scott Hartley, LombardStreet Ventures, Presight Capital, What If Ventures, Tim Kendall, Alexandria Venture Investments, Alpha Wave Ventures, Eli Lilly and Company, Franklin Templeton, Lightswitch Capital, Point72, Windham Venture Partners |
| Sep 19, 2023 | Virtual Incision | $30.0M Series C Extension | Thomas Shehab, MD, MMM, Baird Capital, Bluestem Capital, cultivate(MD), Endeavour Vision, Amy Len, PrairieGold Venture Partners | — |